Resistance to activated protein C, the FV: Q⁵⁰⁶ allele, and venous thrombosis

Summary

Vitamin K-dependent protein C is an important regulator of blood coagulation. After its activation on the endothelial cell surface by thrombin bound to thrombomodulin, it cleaves and inactivates procoagulant cofactors Va and Villa, protein S and intact factor V working as cofactors. Until recently, genetic defects of protein C or protein S were, together with antithrombin III deficiency, the established major causes of familial venous thromboembolism, but they were found in fewer than 5-10% of patients with thrombosis. In 1993, inherited resistance to activated protein C (APC) was described as a major risk factor for venous thrombosis. It is found in up to 60% of patients with venous thrombosis. In more than 90% of cases, the molecular background for the APC resistance is a single point mutation in the factor V gene, which predicts substitution of an arginine (R) at position 506 by a glutamine (Q). Mutated factor V (FV: Q⁵⁰⁶) is activated by thrombin or factor Xa in normal way, but impaired inactivation of mutated factor Va by APC results in life-long hypercoagulability. The prevalence of the FV:Q⁵⁰⁶ allele in the general population of Western countries varies between 2 and 15%, whereas it is not found in several other populations with different ethnic backgrounds. Owing to the high prevalence of FV:Q⁵⁰⁶ in Western populations, it occasionally occurs in patients with deficiency of protein S, protein C, or antithrombin III. Individuals with combined defects suffer more severely from thrombosis, and often at a younger age, than those with single defects, suggesting severe thrombophilia to be a multigenetic disease.

Keywords

APC-resistance - factor V - protein C - protein S - thrombosis

• REFERENCES

• 1 The urokinase pulmonary embolism trial. A national cooperative study. Circulation 1973; 47: 1-108.
• 2 Aiach M, Gandrille S, Emmerich J. A review of mutations causing deficiencies of antithrombin, protein C and protein S. Thromb Haemost 1995; 74: 81-9.
• 3 Allaart RC, Poort SR, Rosendaal FR, Reitsma PH, Bettina RM, Briët E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-8.
• 4 Aparicio C, Dahlbäck B. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gin mutation in the factor V gene. Biochem J 1996; 313: 467-72.
• 5 Arnljots B, Dahlbäck B. Protein S as an in vivo cofactor to activated protein C in prevention of microarterial thrombosis in rabbits. J Clin Invest 1995; 95: 1987-93.
• 6 Arnljots B, Dahlbäck B. Antithrombotic effects of activated protein C and protein S in a rabbit model of microarterial thrombosis. Arterioscler Thromb 95: 1987-93.
• 7 Bakker H, Tans G, Janssen-Classen T, Thomassen MCLGD, Hemker HC, Griffen JH, Rosing J. The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. Eur J Biochem 1992; 208: 171-8.
• 8 Bauer KA. Management of patients with hereditary defects predisposing to thrombosis including pregnant women. Thromb Haemost 1995; 74: 94-100.
• 9 Beauchamp NJ, Daly ME, Cooper PC, Preston FE, Peake IR. Rapid two-stage PCR for detecting factor V G1591A mutation. Lancet 1994; 344: 694-5.
• 10 Ben-Tal O, Zivelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61: 50-4.
• 11 Bertina RM. Hereditary protein S deficiency. Haemostasis 1985; 15: 241-6.
• 12 Bertina RM, Broekmans AW, Van Der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost 1982; 48: 1-5.
• 13 Bertina RM, van Wijngaarden A, Reinalda-poot J, Poort SR, Bom VJ. Determination of plasma protein S - the protein cofactor of activated protein C. Thromb Haemost 1985; 53: 268-72.
• 14 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 15 Beufé S, Borg JY, Vasse M, Charbonnier F, Moreau V, Monconduit M, Frebourg T. Co-segregation of thrombosis with the factor V Q506 mutation in an extended family with resistance to activated protein C. Br J Haematol 1995; 89: 659-62.
• 16 Bovill EG, Bauer KA, Dickermann JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73: 712-7.
• 17 Broekmans AW, Conard J. Hereditary protein C deficiency. In: Protein C and related proteins. Bertina RM. (ed). Edinburgh: Churchill Livingstone; 1988: 160-81.
• 18 Broekmans AW, Veitkamp JJ, Bettina RM. Congenital protein C deficiency and venous thromboembolism: a study in three Dutch families. N Engl J Med 1983; 309: 340-4.
• 19 Cadroy Y, Sié P, Alhenc MGelas, Aiach M. Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated by oral anticoagulants. Thromb Haemost 1995; 73: 734-5.
• 20 Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barrett J, Lane DA, Grant PJ. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vase Biol 1995; 15: 783-5.
• 21 Chafa O, Fischer AM, Meriane F, Chellali F, Rahal S, Sternberg C, Benabadji M. A new case of “type IF’ inherited protein S deficiency. Br J Haematol 1989; 73: 501-8.
• 22 Comp PC, Esmon CT. Recurrent thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-8.
• 23 Comp PC, Nixon RR, Cooper MR, Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082-8.
• 24 Comp PC, Nixon RR, Esmon CT. Determination of functional levels of protein C, an antithrombotic protein, using thrombinthrombomodulin complex. Blood 1984; 63: 15-21.
• 25 Comp PC, Doray D, Patton D, Esmon CT. An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986; 67: 504-8.
• 26 Conard J, Trossaërt M, Horellou MH, Elalamy I, Cheloufi L, Samama MM. Risk of venous thrombosis in 51 women with resistance to activated protein C associated with factor V Leiden. Thromb Haemost 1995; 73: 1375 (Abstract).
• 27 Cook G, Walker ID, McCall F, Conkie JA, Greer IA. Familial thrombophilia and activated protein C resistance: thrombotic risk in pregnancy. Br J Haematol 1994; 87: 873-5.
• 28 Cooper PC, Hampton KK, Makris M, Abuzenadah A, Paul B, Preston FE. Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency. Br J Haematol 1994; 88: 201-3.
• 29 Cripe LD, Moore KD, Kane WH. Structure of the gene for humanm coagulation factor V. Biochemistry 1992; 31: 3777-85.
• 30 Cushman M, Bhushan F, Bovill E, Tracy R. Plasma resistance to activated protein C in venous and arterial thrombosis. Thromb Haemost 1994; 72: 647.
• 31 Dahlbäck B. Human coagulation factor V purification and thrombi-catalyzed activation. J Clin Invest 1980; 66: 583-91.
• 32 Dahlbäck B. Resistance to activated protein C, the Arg506 to Gin mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons. Thromb Haemost 1995; 73: 739-42.
• 33 Dahlbäck B, Stenflo J. High molecular weight complex in human plasma between vitamin K-dependent protein S and complement component C4b-binding protein. Proc Natl Acad Sei USA 1981; 78: 2512-6.
• 34 Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sei USA 1994; 81: 1396-400.
• 35 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sei 1993; 90: 1004-8.
• 36 Dalen JE, Banas JS, Brooks HL, Evans GL, Paraskos JA, Dexter L. Resolution rate of acute pulmonary embolism in man. N Engl J Med 1969; 280: 1194-9.
• 37 Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 1995; 74: 1-6.
• 38 de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
• 39 Demarmels F, Merlo C, Furlan M, Sulzer I, Binder BR, Lämmle B. Prevalence of APC resistance in 134 survivors of myocardial infarction. Thromb Haemost 1995; 73: 1125 (Abstract).
• 40 De Stefano V, Mastrangelo S, Paciaroni K, Ireland H, Lane DA, Bizzi B, Leone G. Prevalence of venous thrombosis in pregnant women with APC-resistance: a retrospective study. Thromb Haemost 1995; 73: 1375 (Abstract).
• 41 Denninger MH, Beldjord K, Durand F, Dénié C, Valla D, Guillin MC. Budd-Chiari syndrome and factor V Leiden mutation. Lancet 1995; 345: 525-6.
• 42 Discipio RG, Hermodson MA, Yates SG, Davie EW. A comparison of human prothrombin, factor IX, factor X, and protein S. Biochemistry 1977; 16: 698-706.
• 43 Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Gambien F. Myocardial infarction. Arg506 to Gin factor V mutation, and activated protein C resistance. Lancet 1995; 345: 321.
• 44 Engesser L, Broekmans AW, Briët E, Brommer EJP, Bertina RM. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 1987; 106: 677-82.
• 45 Eritsland J, Gjonnes G, Sandset PM, Seljeflot I, Arnesen H. Activated protein C resistance and graft occlusion after coronary artery bypass surgery. Thromb Res 1995; 79: 223-6.
• 46 Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12: 135-45.
• 47 Esmon CT, Stenflo J, Suttie JW, Jackson CM. A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase. J Biol Chem 1976; 251: 3052-6.
• 48 Fair DS, Marlar RA. Biosynthesis and secretion of factor VII, protein C, protein S, and the protein C inhibitor from a human hepatoma cell line. Blood 1986; 67: 64-70.
• 49 Fauno P, Ravn HB, Lassen JF. Lund ED, Jensen ED. Association between activated protein C resistance and postoperative deep vein thrombosis. Thromb Haemost 1995; 73: 1371 (Abstract).
• 50 Forsyth PD, Dolan G. Activated protein C resistance in cases of cerebral infarction. Lancet 1995; 345: 795.
• 51 Fulcher CA, Roberts JR, Zimmerman TS. Thrombin proteolysis of purified factor VIII procoagulant protein: correlation of activation with generation of a specific polypeptide. Blood 1983; 61: 807-11.
• 52 Fulcher CA, Gardiner JE, Griffen JH, Zimmermann TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63: 486-9.
• 53 Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-18.
• 54 Gandrille S, Greengard JS, Alhenc MGelas, Juhan-Vague I, Abgrall JF, Jude B, Griffin JH, Aiach M. the French network on behalf of INSERM. Incidence of activated protein C resistance caused by the ARG 506 Gin mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 1995; 86: 219-24.
• 55 Gladson CL, Scharrer I, Hach V, Beck KH, Griffen JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18-22.
• 56 Goldhaber SZ. Epidemiology of pulmonary embolism and deep vein thrombosis. In: Haemostasis and thrombosis. Tuddenham EGD, Bloom AL, Forbes CD, Thomas DP. a(eds). Edinburgh: Churchill Livingstone; 1994: 1327-33.
• 57 Greengard JS, Eichinger S, Griffen JH, Bauer KA. Brief report: variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg —» Gin mutation in the gene for factor V. N Engl J Med 1994; 331: 1559-62.
• 58 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt BL. Activated protein C resistance caused by Arg506 Gin mutation in factor Va. Lancet 1994; 343: 1362-3.
• 59 Griffin JH, Evatt BL, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-3.
• 60 Griffin JH, Evatt BL, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-93.
• 61 Halbmayer WM, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 1994; 05: 51-7.
• 62 Hallam PJ, Millar DS, Krawczak M, Kakkar VV, Cooper DN. Population differences in the frequency of the factor V Leiden variant among people with clinically symptomatic protein C deficiency. J Med Genet 1995; 32: 543-5.
• 63 Harris KW, Esmon CT. Protein S is required for bovine platelets to support activated protein C binding and activity. J Biol Chem 1985; 260: 2007-10.
• 64 Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872-7.
• 65 Heeb MJ, Rosing J, Bakker HM, Fernandez JA, Tans G, Griffin JH. Proteins S binds to and inhibits factor Xa. Proc Natl Acad Sei USA 1994; 91: 2728-32.
• 66 Heeb MJ, Kojima Y, Greengard JS, Griffen JH. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995; 85: 3405-11.
• 67 Heijboer H, Brandjes D, Biiller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-6.
• 68 Heinrich J, Schulte H, Funke H, Schönfeld R, Köhler E, Assmann G. Frequency of point mutation in factor V gene (1691 G/A), which is associated with resistance to activated protein C, in coronary artery disease patients. Thromb Haemost 1995; 73: 1125 (Abstract).
• 69 Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173: 210-3.
• 70 Holm J, Zöller B, Svensson PJ, Berntorp E, Erhardt L, Dahlbäck B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994; 344: 952-3.
• 71 Holm J, Zöller B, Berntorp E, Erhardt L, Dahlbäck B. Prevalence of factor V gene mutation among myocardial infarction patients and healthy controls higher in Sweden than in other countries. J Intern Med. 1996 (in press).
• 72 Hopmeier P, Krugluger W. Factor V Leiden and thrombophilia. N Engl J Med 1995; 332: 1381-2.
• 73 Iijima K, Inoue N, Nakamura K, Fukuda C, Ohgi S, Okada M, Mori T, Nishioka J, Hayashi T, Suzuki K. Inherited deficiency of functional and free-form protein S. Acta Haematol Japan 1989; 52: 126-33.
• 74 Ikeda K, Stenflo J. A radioimmunoassay for protein C. Thromb Res 1985; 39: 297-306.
• 75 Ireland H, Bayston T, Chowdhury V, Thein SL, Conard J, Pabinger I, Lane DA. Factor V Leiden as an independent risk factor for thrombosis in antithrombin deficiency type II: heparin binding site. Thromb Haemost 1995; 73: 1361 (Abstract).
• 76 Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance. Lancet 1994; 344: 1162-3.
• 77 Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-80.
• 78 Kalafatis M, Bettina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270: 4035-7.
• 79 Kamiya T, Sugihara T, Ogata K, Saito H, Suzuki K, Nishioka J, Hashimoto S, Yamagata K. Inherited deficiency of protein S in a Japanese family with recurrent venous thrombosis; a study of three generations. Blood 1986; 67: 406-10.
• 80 Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 71: 539-55.
• 81 Kisiel W. Human plasma protein C. Isolation, characterization and mechanism of activation by a-thrombin. J Clin Invest 1979; 64: 761-9.
• 82 Kisiel W, Canfield WM, Ericsson LH, Davie EW. Anticoagulant properties of bovine plasma protein C following activation by thrombin. J Biol Chem 1977; 16: 5824-31.
• 83 Koeleman BPC, Reitsma PH, Allaart RC, Bettina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
• 84 Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinenmakelin RK, Hamalainen L, Palomaki H, Kaste M. Arg606Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558-60.
• 85 Koster T, Rosendaal FR, de Ronde F, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosus due to poor response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
• 86 Lauer CG, Reid TJ, Wideman CS, Evatt BL, Alving BM. Free protein S deficiency in a family with venous thrombosis. J Vase Surg 1990; 12: 541-4.
• 87 Levoir D, Emmerich J, Alhenc MGelas, Dumontier I, Petite JP, Fiessinger JN, Aiach M. Portal vein thrombosis and factor V Arg 506 to Gin mutation. Thromb Haemost 1995; 73: 550-1.
• 88 Lilienfeld DE, Chan E, Ehland J, Godbold JH, Landrigan PJ, Marsh G. Mortality from pulmonary embolism in the United States: 1962 to 1984. Chest 1990; 98: 1067-72.
• 89 März W, Seydewitz H, Winkelmann B, Chen M, Nauck M. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995; 345: 526-7.
• 90 Mahmoud AEA, Wilde JT, Elias E. BuddChiari syndrome and factor V Leiden mutation. Lancet 1995; 345: 526.
• 91 Majerus PW. Bad blood by mutation. Nature 1994; 369: 14-5.
• 92 Malm J, Laurell M, Dahlbäck B. Changes in the plasma levels of vitamin K-dependent proteins C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 1988; 68: 437-44.
• 93 Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease critical evaluation of laboratory investigation. Thromb Haemost 1992; 68: 7-13.
• 94 Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990; 16: 299-309.
• 95 Marlar RA, Kleiss AJ, Griffin JH. Human protein C: inactivation of factors V and VIII in plasma by the activated molecule. Ann NY Acad Sei 1981; 370: 303-10.
• 96 Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993; 72: 477-80.
• 97 Miletich JP, Sherman L, Broze Jr GJ. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-6.
• 98 Monreal M, Ruiz J, Salvador R, Morera J, Arias A. Recurrent pulmonary embolism. A prospective study. Chest 1989; 95: 976-9.
• 99 Nemerson Y. Tissue factor: then and now. Thromb Haemost 1995; 74: 180-4.
• 100 Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 1979; 254: 10952-62.
• 101 Nicolaes GAF, Tans G, Thomassen MCLGD, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor y_aR506Q by activated protein C. J Biol Chem 1995; 270: 21158-66.
• 102 Pabinger I, Mustafa S, Rintelen C, Kyrle PA, Lechner K, Mannhalter C. Factor V (FV) Leiden mutation (APC-resistance) increases the risk for venous thromboembolism in patients with a gene defect of the protein C (PC) or protein S (PS) gene. Thromb Haemost 1995; 73: 1361 (Abstract).
• 103 Pini M, Manotti C, Pattacini C, Quintavalla R, Tagliaferri A, Poli T, Bernardi F. High prevalence of activated protein C resistance in young women with venous thromboembolic events occurred during treatment with oral contraceptives. Thromb Haemost 1995; 73: 1376 (Abstract).
• 104 Radtke KP, Lane DA, Greengard JS, Ehrenforth S, Griffin JH, Scharrer I. Combined hereditary APC resistance and ATIII type II deficiency associated with venous thrombosis. Thromb Haemost 1995; 73: 1377 (Abstract).
• 105 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
• 106 Regan LM, Lamphear BJ, Walker FJ, Fay PJ. Factor IXa protects factor Villa from activated protein C: factor IXa inhibits activated protein C-catalyzed cleavage of factor Villa at Arg⁵⁶² . J Biol Chem 1994; 269: 9445-52.
• 107 Reitsma PH, Ploos van Amstel HK, Poort BR, van der Velden PA, Bertina RM. Molecular basis of hereditary protein C and protein S deficiency. Curr Stud Hematol Blood Transfus 1991; 58: 94-9.
• 108 Reitsma PH, Poort SR, Allaart RC, Briët E, Bertina RM. The spectrum of genetic defects in a panel of 40 Dutch families with symptomatic protein C deficiency type I: heterogeneity and founder effects. Blood 1991; 78: 890-4.
• 109 Reitsma PH, Bernardi F, Doig RG, Gandrille S, Greengard JS, Ireland H, Krawczak M, Lind B, Long GL, Poort SR, Saito H, Sala N, Witt I, Cooper DN. Protein C deficiency: a database of mutations, 1995 update. Thromb Haemost 1995; 73: 876-89.
• 110 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
• 111 Rosén S, Johansson K, Lindberg K, Dahlbäck B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 1994; 72: 255-60.
• 112 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance).. Blood 1995; 85: 1504-8.
• 113 Sala N, Owen WG, Collen D. A functional assay of protein C in human plasma. Blood 1984; 63: 671-5.
• 114 Samani N, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and risk of premature myocardial infarction. Lancet 1994; 344: 1709-10.
• 115 Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297300.
• 116 Seligsohn U, Berger A, Abend A, Rubin L, Attias D, Zivelin A, Rapaport SI. Homozygous protein C deficiency manifested by massive thrombosis in the newborn. N Engl J Med 1984; 310: 55962.
• 117 Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem 1994; 269: 187358.
• 118 Shizuka R, Kanda T, Amagi H, Kobayashi I. Falsepositive activated protein C (APC) sensitivity ratio caused by freezing and by contamination of plasma with platelets (letter to editor in chief).. Thromb Res 1995; 78: 18990.
• 119 Simioni P, Battistella PA, Drigo P, Carollo C, Girolami A. Childhood stroke associated with familial protein S deficiency. Brain Dev 1994; 16: 2415.
• 120 Simioni P, Scudeller A, Girolami A. Factor V Leiden and thrombophilia. N Engl J Med 1995; 332: 1382.
• 121 Solymoss S, Tucker MM, Tracy PB. Kinetics of inactivation of membranebound factor V by activated protein C. J Biol Chem 1988; 263: 1488490.
• 122 Soskolne CL, Wong AW, Lilienfeld DE. Trends in pulmonary embolism death rates for Canada and the United States, 196287. Can Med Assoc J 1990; 142: 3214.
• 123 Stenflo J. A new vitamin Kdependent protein. J Biol Chem 1976; 251: 35563.
• 124 Stern DM, Nawroth PP, Harris KW, Esmon CT. Cultured bovine aortic endothelial cells promote activated protein C protein Smediated inactivation of factor Va. J Biol Chem 1986; 261: 7138.
• 125 Sun X, Evatt BL, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 31205.
• 126 Suzuki K, Dahlbäck B, Stenflo J. Thrombincatalyzed activation of human coagulation factor V. J Biol Chem 1982; 257: 655664.
• 127 Suzuki K, Stenflo J, Dahlbäck B, Teodorson B. Inactivation of human coagulation factor V by activated protein C. J Biol Chem 1983; 258: 191420.
• 128 Suzuki K, Nishioka J, Matsuda J, Maruyama I, Hashimoto S. Protein S is essential for the activated protein Ccatalyzed inactivation of plateletassociated factor Va. J Bio chem 1984; 96: 45560.
• 129 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 51721.
• 130 Tabernero MD, Tomas JF, Alberca I, Orfao A, Borrasca AL, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hermatol 1991; 36: 24954.
• 131 Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 36990.
• 132 Thiel F, Ehrenforth B, Zwinge B, Dingeldein E, Scharrer I. Relation between APC resistance and juvenile stroke. Thromb Haemost 1995; 73: 1401 (Abstract).
• 133 Tosetto A, Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost 1995; 73: 7323.
• 134 Tow DE, Wagner HN. Recovery of pulmonary arterial blood flow in patients with pulmonary embolism. N Engl J Med 1967; 276: 10539.
• 135 Trossaërt M, Conard J, Horellou MH, Samama MM, Ireland H, Bayston TA, Lane DA. Modified APC resistance assay for patients on oral anticoagulants. Lancet 1994; 344: 1709.
• 136 van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. Nature Med 1995; 01: 185.
• 137 van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer K, Scharrer I, Lane DA. Interaction of factor V Leiden with inherited antithrombin deficiency. Thromb Haemost 1995; 73: 1256 (Abstract).
• 138 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 14537.
• 139 van der Bom JG, Kluft C, Bots ML, Haverkate F, Slagboom E, Meijer P, Grobbee DE. Factor V mutation. APC resistance and myocardial infarction in the Rotterdam study. Thromb Haemost 1995; 73: 1373 (Abstract).
• 140 Viigimaa M, Saareoja Y. Prospective study on activated protein C resistance in patients with acute myocardial infarction. Thromb Haemost 1995; 73: 1374 (Abstract).
• 141 Voorberg J, Roelse J, Koopman R, Biiller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V. Lancet 1994; 434: 15356.
• 142 Walker FJ. Regulation of activated protein C by a new protein. J Biol Chem 1980; 255: 55214.
• 143 Walker FJ. Regulation of activated protein C by protein S, the role of phospholipid in factor Va inactivation. J Biol Chem 1981; 256: 1112831.
• 144 Walker FJ, Sexton PW, Esmon CT. The inhibition of blood coagulation by activated protein C through the selective inactivation of activated factor V. Biochem Biophys Acta 1979; 571: 33342.
• 145 Walker FJ, Chavin SI, Fay PJ. Inactivation of factor VIII by activated protein C and protein S. Arch Biochem Biophys 1987; 252: 3228.
• 146 Wheeler AP, Jaquiss RDB, Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med 1988; 148: 13215.
• 147 Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 15368.
• 148 Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosisprone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 25214.
• 149 Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 351-823.
• 150 Zöller B, Garcia de Frutos P, Dahlbäck B. Evaluation of the relationship between protein S and C4bbinding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995; 85: 352431.
• 151 Zöller B, He X, Dahlbäck B. Homozygous APCresistance combined with protein S deficiency in a young boy with severe thrombotic disease. Thromb Haemost 1995; 73: 7435.
• 152 Zöller B, Holm J, Svensson PJ, Dahlbäck B. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with inherited APCresistance and/or protein S deficiency. Thromb Haemost 1996; 75: 2704.